← Browse by Condition
Medical Condition

adenoid cystic carcinoma

Total Trials
4
Recruiting Now
4
Trial Phases
Phase 2

ClinicalMetric tracks all active clinical trials for adenoid cystic carcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — adenoid cystic carcinoma Clinical Trials

How many clinical trials are currently recruiting for adenoid cystic carcinoma?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for adenoid cystic carcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for adenoid cystic carcinoma?
adenoid cystic carcinoma research spans Phase 2 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a adenoid cystic carcinoma clinical trial?
Eligibility criteria for adenoid cystic carcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
3
Top Sponsors
Heidelberg University 1 trial
Dana-Farber Cancer Institute 1 trial
Instituto do Cancer do Estado de São Paulo 1 trial
Memorial Sloan Kettering Cancer Center 1 trial

Recruiting Clinical Trials

NCT04214366 Phase 2
Recruiting

Adenoid Cystic Carcinoma and Carbon Ion Only Irradiation

Enrollment
314 pts
Location
Germany
Sponsor
Heidelberg University
View Trial →
NCT04883671
Recruiting

Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial

Enrollment
32 pts
Location
United States
Sponsor
Dana-Farber Cancer Institute
View Trial →
NCT06638931 Phase 2
Recruiting

Agnostic Therapy in Rare Solid Tumors

Enrollment
28 pts
Location
Brazil
Sponsor
Instituto do Cancer do Estado ...
View Trial →
NCT06891560 Phase 2
Recruiting

A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma

Enrollment
34 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology